Frontlight ResearchEarly access
WithdrawnNo phase
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
Key facts
- Who runs it
- Boehringer Ingelheim
- Where
- Germany, Netherlands, Spain, and Sweden6 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 24 Nov 2022
- Ended
- 1 Oct 2024
- Type of study
- Observational
- Treatments tested
- Dabigatran Etexilate (DE)
- Record updated
- 26 June 2024
- Why it stopped
- No patients were screened in the study.
Who can take part
- Age
- Up to 2 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Written informed consent from parents/care givers
- Children from birth to less than 2 years of age
- Initiation of Dabigatran Etexilate (DE) administration:; for treatment of Venous thromboembolism (VTE) or/and; prevention of recurrent VTE due to presence of unresolved clinical VTE risk factor(s)
Who cannot take part
- Participation in any Randomised Clinical Trial or use of any investigational product
- Any contraindications to DE according to the EU Summary of Product Characteristics (SmPC)
Where is this trial?
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is designed to collect and evaluate Dabigatran Etexilate (DE) safety in the context of routine anticoagulation care provided in the European Union (EU)/European Economic Area (EEA) for children under 2 years of age.
Read full original descriptionShow less
The non-interventional study will be conducted in paediatric hospitals or paediatric departments of EEA member states where Venous thromboembolism (VTE) patients of the evaluated age group are treated.
The group in the trial
- Pediatric patients eligible for Dabigatran Etexilate (DE) VTE treatment and secondary VTE prevention
Treatment: Dabigatran Etexilate (DE)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety of Dabigatran Etexilate (DE) for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Paediatric Patients From Birth to Less Than 2 Years of Age: a Prospective European Non-interventional Cohort Study Based on New Data Collection
- Record updated
- 26 June 2024